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Risk factorsAbstract Multidrug resistance and production of extended spectrum b-lactamases (ESBLs) by
enteric gram negative rods in hospitals and community continue to be a matter of scientiﬁc concern.
This retrospective study was executed to assess the prevalence of ESBL-producing Escherichia coli
and Klebsiella pneumoniae at two North Indian hospitals and to determine the risk factors associ-
ated with the acquisition of these organisms. A total of 346 bacterial isolates were obtained. Of
these, 48.27% (n= 167) were conﬁrmed to be ESBL producers while 51.73% (n= 179) were
non ESBL-producers. Among the ESBL producers, 55.69% (n= 93) were E. coli and 44.31%
(n= 74) were K. pneumoniae. ESBL producing isolates showed co-resistance to multitude of anti-
biotics tested. Length of hospital stay (>3 days) and previous exposure to antibiotics were found as
signiﬁcant risk factors (p= 0.01 and 0.02) associated with the acquisition of ESBL-producing
E. coli and K. pneumoniae isolates. Imipenem and meropenem can be suggested as drugs of choice
in our study.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Multidrug resistance and production of extended spectrum
b-lactamases (ESBLs) by enteric gram negative rods in hospi-
tals and community continue to be a matter of scientiﬁc
concern. Continued selective pressure has lead to the emer-
gence of multiple-drug-resistant (MDR) bacteria. Multidrug
resistance is an inevitable genetic response to misappropriated
exposures of pathogen populations to antibiotics (Sheikh et al.,
2003).
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There is a widespread occurrence of ESBLs, particularly in
the hospital environment. ESBLs exhibited resistance to
third-generation cephalosporins and are now a menace to hos-
pitalized patients globally (Paterson and Bonomo, 2005;
Pfaller and Segreti, 2006).
ESBLs are bacterial enzymes that confer resistance to
advanced generation cephalosporins and can lead to the ther-
apeutic failure of these agents. ESBLs are often plasmid asso-
ciated and there can be cross-species dissemination of these
plasmids. Moreover, these plasmids often carry genes encoding
co-resistance to other antibiotics such as aminoglycosides, tet-
racyclines, chloramphenicol, ﬂuoroquinolones and sulfameth-
oxazole–trimethoprim, to name a few. Concomitant b-lactam
and aminoglycoside resistance is increasingly being reported
(Ma et al., 2009).
Escherichia coli and Klebsiella pneumoniae remain the dom-
inant ESBL-producing organisms isolated globally (Jacoby
and Munoz-Price, 2005; Fatemeh et al., 2012). Antibacterial
resistance of Enterobacteriaceae, especially the emergence of
MDR strains is an important clinical problem worldwide
(Giske et al., 2008; Abhijit et al., 2013; Majda et al., 2013).
Resistance to a wide variety of common antimicrobials has
made the proliferation of ESBL-producing strains a serious
global health concern that has complicated treatment strategies.
The high proportion of ESBL producers among the Enterobac-
teriaceae and the complex molecular epidemiology with diverse
types of ESBL genes involved therein are alarming. The aim of
this retrospective study was to determine the prevalence and
antimicrobial susceptibility pattern of ESBL producing enteric
Gram-negative bacteria and also to identify the risk factors
associated with the acquisition of these organisms.
2. Methods
2.1. Sample and data collection
The study was conducted for a period of 12 months (March
2013 to February 2014) at two North Indian hospitals (Luc-
know region). Both of these were multispecialty hospitals
(approximately 900 bedded each). A total of 346 isolates were
obtained from clinical samples during this study admitted into
various units like medical, surgical, pediatric, ophthalmologic,
orthopedic units as well as neonatal intensive care units. The
isolates were obtained from the cultures of specimens from
patients hospitalized for >48 h. The ‘length of hospital stay’
was deﬁned as the period between the date of admission of
patients to the hospital and the date of sample collection.
The sources of these isolates were urine (113), blood (43), spu-
tum (36), eye discharges (76), surface swabs (57) and body ﬂu-
ids (21). Demographic and other relevant details were retrieved
from patient record ﬁles. All the specimens were quickly sent
to the laboratory to be processed for microbial pathogens.
Standard methods for isolation and identiﬁcation of these bac-
teria were used (Cowan and Steel, 1970).
2.2. Antimicrobial susceptibility testing and ESBL detection
Antimicrobial susceptibility testing of the isolates was performed
by the standard disk diffusion method as recommended by
the Clinical and Laboratory Standards Institute (CSLI, 2008).Isolates for which the minimum inhibitory concentration
(MIC) of ceftazidime and/or cefotaxime was >2 lg ml1, which
was obtained by microbroth dilution method, were classiﬁed as
probable ESBL-producers. The results were reconﬁrmed by
using HiCombMIC test strips as per the manufacturer’s instruc-
tions (Himedia, Mumbai, India). The ESBL phenotypic
conﬁrmatory test with ceftazidime, cephotaxime, ceftriaxone
and ceﬁxime was performed for all the probable isolates by disk
diffusion method on Mueller–Hinton agar plates with and
without 10 lg of amoxicillin/clavulanate. A P5 mm increase
in the zone of diameter of third generation cephalosporins, tested
in combination with amoxyclav versus its zone when tested alone
was considered indicative of ESBL production. E. coli ATCC
25922 was used as ESBL negative and K. pneumoniae 700603
was used as ESBL-positive reference strain.
2.3. Statistical analysis
The association of study variables with ESBL and non-ESBL-
producing E. coli and/or K. pneumoniae acquisition status was
tested by using Student’s t-test or Fisher’s exact test as
appropriate. The odds ratios (ORs) with 95% conﬁdence
intervals (CIs) for having ESBL associated acquisitions were
calculated. A two-tailed p value of <0.05 was taken as signif-
icant. Statistical analysis was performed using SISA software.
3. Results
A total of 346 bacterial isolates were obtained from clinical
samples during the 12 month study period from patients to dif-
ferent units of the hospital. Of these 48.27% (n= 167) were
found to be ESBL producers while 51.73% (n= 179) were
non ESBL producers. Among the ESBL producers, 55.69%
(n= 93) were conﬁrmed to be E. coli while 44.31% (n= 74)
were identiﬁed as K. pneumoniae. Antibiotic susceptibility tests
were performed for ESBL producing isolates. Imipenem and
meropenem were found to be the most effective antibiotics
against the ESBL-producing E. coli and K. pneumoniae strains.
Zero percent resistance was found against imipenem in the case
of K. pneumoniae while it was 2.5% (n= 2) in the case of
E. coli. 1.08% (n= 1) resistance was observed against merope-
nem in the case of E. coli while it was 2.70% (n= 2) in the case
of K. pneumoniae isolates. 53.76% (n= 50) E. coli isolates
were found to be resistant against cefepime while 51.35%
(n= 38) resistant was observed for K. pneumoniae isolates.
Both E. coli and K. pneumoniae isolates were found to be resis-
tant against amikacin. Among the third-generation cephalo-
sporins, maximum resistance was found against Ceftriaxone,
which was 78.49% (n= 73) and 79.73% (n= 59) for E. coli
and K. pneumoniae isolates, respectively. The percent resis-
tance to selected antimicrobials exclusively among the ESBL-
producing isolates has been shown in Table 1.
The mean age of patients harboring ESBL producing iso-
lates was found to be 38.65 years (SD 11.32) while the same
was 39.84 years (SD 12.15) for the patients harboring non-
ESBL producing E. coli and K. pneumoniae strains. Mean
duration of hospital stay was observed as 5.63 (SD 1.15) days
among patients harboring ESBL producing organisms while
the same was 2.13 (SD 0.56) days among patients with
non-ESBL producing isolate acquisition. The length of
hospital stay (>3 days) was found to be a signiﬁcant risk
Table 1 Percentage of resistance to the selected antimicrobial agents among the ESBL-positive isolates.
S. no. Antibiotics E. coli n= 93 K. pneumoniae n= 74
S R %R S R %R
1 Ampicillin 08 85 91.39 07 67 90.54
2 Aztreonam 14 79 84.95 05 69 93.24
3 Amikacin 25 68 68.81 30 44 59.46
4 Cefotaxime 22 71 76.34 16 58 78.38
5 Ceftazidime 33 60 64.52 24 50 67.57
6 Cefazolin 25 68 73.11 18 56 75.68
7 Cefepime 43 50 53.76 36 38 51.35
8 Cefoxitin 34 59 63.44 19 55 74.32
9 Ceftriaxone 20 73 78.49 15 59 79.73
10 Ciproﬂoxacin 40 53 56.99 20 54 72.97
11 Piperacillin 24 69 74.19 24 50 67.57
12 Tigecycline 36 57 61.29 21 53 71.62
13 Gentamicin 23 70 75.27 16 58 78.38
14 Imipenem 91 02 2.15 74 00 00.00
15 Meropenem 92 01 1.08 72 02 2.70
S = Sensitive, R = Resistant.
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Prior exposure to beta lactams, and Aminoglycoside/ﬂuoro-
quinolone antibiotics was also found as a signiﬁcant risk factor
for ESBL producing isolate acquisition (p= 0.04 and 0.02).
Stay in ICU, presence of an invasive device and underlying ill-
ness were not found as signiﬁcant risk factors in the present
study. The demographic and clinical characteristics of the
patients have been shown in Table 2.
4. Discussion
ESBLs have become widespread in hospital as well as commu-
nity settings (Pfaller and Segreti, 2006; Shakil et al., 2010).
These enzymes are becoming increasingly expressed by many
strains of pathogenic bacteria with a potential for dissemina-
tion. Presence of ESBLs compromises the activity of a wide
spectrum of antibiotics creating major therapeutic difﬁculties
with a signiﬁcant impact on the outcome of patients. The
continued emergence of ESBLs presents a serious diagnostic
challenge to the clinical microbiology laboratories (Meeta
et al., 2013).
In the present study, we observed that 55.69% (n= 93) of
the E. coli and 44.31% (n= 74) of the K. pneumoniae isolates
were ESBL producers. ESBL production was more common
among the E. coli isolates as compared to the K. pneumoniae
isolates which is in harmony with the ﬁnding of other studies
(Tankhiwale et al., 2004; Babypadmini and Appalaraju,
2004; Umadevi et al., 2011).
The ESBL producing isolates showed co-resistance against
most of the antibiotics tested, which was consistent with most
of the recent ﬁndings (Fanos et al., 2007; Shakil et al., 2009;
Shahla and Samaneh, 2010; Shanthi and Sekar, 2010; Majda
et al., 2013). ESBL-producers are frequently resistant to
advance generation cephalosporins. However, in the present
study some ESBL producing isolates showed susceptibility to
advance generation cephalosporins (cefotaxime, ceftazidime,
and ceftriaxone). This could happen due to the incidental pres-
ence of various other mechanisms of resistance and counter
resistance in a given bacterium. This was in harmony withpreviously published studies in which authors have reported
ESBL producing isolates that were susceptible to advance gen-
eration cephalosporins (Shakil et al., 2009; Thakur et al., 2013;
Ahmed et al., 2013). All ESBL producing E. coli and K. pneu-
moniae isolates were sensitive to imipenem and meropenem.
This is in harmony with the ﬁndings of Iraj and Nilufar,
2010. The authors have suggested carbapenems as drugs of
choice for the treatment of ESBL related infections (Iraj and
Nilufar, 2010).
The length of hospital stay (>3 days) and prior exposure to
beta lactam and aminoglycosides/ﬂuoroquinolones antibiotics
were also found as signiﬁcant risk factors (p= 0.01 and 0.02,
respectively) for acquisition of ESBL producing isolates. This
is coherent to the ﬁnding of Shanthi and Sekar, 2010. Under-
lying illness, presence of an invasive device and prolonged dis-
ease were not found to be signiﬁcantly associated with the
acquisition of ESBL-producing E. coli and K. pneumoniae
among the patients studied.
ESBL producing gram negative bacteria have been respon-
sible for numerous outbreaks of infection worldwide and
therefore, pose a challenge to efﬁcient infection control. So it
is essential to identify ESBLs as a routine in the hospitals.
ESBL-detection in a hospital indicates the need for use of
appropriate antibiotic prescribing practices. ESBLs are found
in certain genera of the Enterobacteriaceae family including
E. coli and K. pneumoniae and other bacteria like Staphylococ-
cus aureus, Haemophilus inﬂuenza and Pseudomonas aeruginosa
(Vandana and Honnavar, 2009). The occurrence of ESBL
among clinical isolates varies greatly worldwide and geograph-
ically and is rapidly changing over time (Babypadmini and
Appalaraju, 2004).
During the last several decades, the prevalence of MDR
organisms in hospitals and medical centers has increased stea-
dily. The prevalence of Gram negative bacteria resistant to
third generation cephalosporins, ﬂuoroquinolones, carbapen-
ems, and aminoglycosides has also increased (Kritu et al.,
2013).
ESBL-producing organisms pose unique challenges to clin-
ical microbiologists, clinicians, infection control professionals
Table 2 Study characteristics in two groups of patients according to acquisition of ESBL-producing and Non-ESBL-producing E. coli
and/or K. pneumoniae isolates.
Characteristics Acquisition of ESBL
Producing E. coli and/or
K. pneumoniae n= 167
Acquisition of non-ESBL
Producing E. coli and/or
K. pneumoniae n= 179
p-Value OR (95% CI)
Mean age 38.65 (SD 11.32) 39.84 (SD 12.15) 0.10 1.19 (0.65–3.03)
Sex
Male 116 (69.46) 95 (53.07) – 1.00
Female 66 (39.52) 69 (38.54) 0.27 1.28 (0.83–1.97)
Length of hospital stay
63 days 51 63 – 1.00
>3 days 136 96 0.01* 0.57 (0.36–0.90)
Mean duration of hospital stay (days) 5.63 (SD 1.15) 2.13 (SD 0.56) 1.00 3.50 (3.41–3.58)
Underlying illness
Diabetes 43 (25.75) 61 (34.08) 0.09 0.67 (0.42–1.07)
Typhoid 27 (16.17) 31 (17.32) 0.77 0.92 (0.52–1.62)
Conjunctivitis 35 (20.96) 41 (22.91) 0.66 0.94 (0.72–1.23)
Others 51 (30.54) 57 (31.84) 0.68 1.10 (0.60–1.75)
Stay in ICU 57 (34.13) 46 (25.70) 0.09 1.50 (0.94–2.38)
Non ICU 113 (67.66) 130 (72.63) 0.31 0.79 (0.50–1.25)
Ventilated 67 (40.12) 59 (32.96) 0.17 1.36 (0.88–2.11)
Non ventilated 109 (65.27) 111 (62.01) 0.53 1.15 (0.74–1.79)
Exposure to antibiotics
Beta-lactams 37 (22.16) 57 (31.84) 0.04* 0.61 (0.38–0.99)
Aminoglycosides/ﬂuoroquinolones 27 (16.16) 47 (26.25) 0.02* 0.52 (0.22–0.92)
OR= odds ratio, CI = conﬁdence interval, SD = standard deviation.
* P value <0.05 is signiﬁcant.
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ESBL-producing strains are usually found in those hospitals
where antibiotic use is frequent and the patients are in critical
condition (Shahanara et al., 2013).
Since ESBL production is more common among the noso-
comial pathogens, early detection will deﬁnitely help in con-
trolling hospital infections which are caused by this group of
organisms. Enterobacteriaceae are the common isolates in
most of the laboratories. Now-a-days, a majority of these iso-
lates are MDR. The control of these MDR organisms is a ther-
apeutic challenge. This difﬁculty is enhanced further by the co-
existence of the resistance to b-lactams, aminoglycosides and
ﬂuoroquinolones, as observed in our study. Of all the available
antimicrobial agents, carbapenems are the most effective and
reliable treatment options for infections which are caused by
the ESBL producing isolates (Paterson and Bonomo, 2005).
5. Conclusion
Problems associated with ESBL producing isolates include
multidrug resistance, difﬁculty in treatment, and increased
mortality of patients. Most of our study isolates were found
to be resistant against four or more antibiotics. Imipenem
and meropenem can be suggested as drugs of choice in our
study. Length of hospital stay and prior exposure to antibiotics
were found to be signiﬁcant risk factors associated with ESBL-
producing E. coli and/or K. pneumoniae acquisition status of
patients. Therefore, restricting the use of third-generation
cephalosporins, along with implementation of infection con-
trol measures, are the most effective means of controlling
and decreasing the spread of ESBL producing pathogens.Acknowledgements
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